Latest news with #HealthQuestCapital
Associated Press
15-05-2025
- Business
- Associated Press
Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy
Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma CHANHASSEN, Minn., May 15, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM) – one of the most aggressive and deadly forms of brain cancer. Backed by leading healthcare investors, the round was co-led by HealthQuest Capital and Samsara BioCapital with participation from existing investors OrbiMed and Action Potential Venture Capital. In addition, venture investors committed to transforming cancer care participated, including BrightEdge, the impact investment and innovation arm of the American Cancer Society, the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, and Sontag Innovation Fund, a subsidiary of The Sontag Foundation. 'The complex and diffuse nature of glioblastomas has long hindered therapeutic innovation,' said Conrad Wang M.D., Partner at HealthQuest Capital. 'Alpheus' sonodynamic therapy represents a novel, non-invasive whole brain approach with compelling early data. This investment reflects our commitment to advancing transformative technologies that seek to fill critical gaps in patient unmet needs.' Alpheus' platform delivers non-thermal, tumor-selective therapy activated by low-intensity diffuse ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA). Without the need for imaging or sedation, this combination selectively targets and destroys cancer cells across the entire brain hemisphere. This novel treatment option is performed in an outpatient setting. Promising early results from two studies highlight the potential of SDT therapy in both newly diagnosed and recurrent glioblastoma patients. 'This investment is a key inflection point for Alpheus and the glioblastoma community – advancing sonodynamic therapy from promise to clinical validation,' commented Vijay Agarwal, MD, FAANS, FCNS, President and CEO of Alpheus Medical. 'With this support, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors.' About Alpheus Medical, Inc. Alpheus Medical is a private, clinical-stage oncology company developing a groundbreaking, non-invasive treatment for solid tumors utilizing sonodynamic therapy (SDT). Its proprietary platform combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA), a sensitizing agent that selectively accumulates in tumor cells. This targeted approach aims to destroy cancer cells while sparing healthy tissue. Alpheus collaborates with global leaders in neuro-oncology and is supported by top healthcare investors and the venture vehicles of nonprofit organizations focused on cancer. Learn more at About HealthQuest Capital HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately $2 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry. For more information, visit About Samsara BioCapital Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs. Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-two years of industry experience and has an MD and a PhD in Immunology from Stanford University. Media Contact Carla Benigni [email protected] View original content to download multimedia: SOURCE Alpheus Medical
Associated Press
15-04-2025
- Business
- Associated Press
hellocare.ai Raises $47M to Accelerate AI-Assisted Virtual Care and Transform Hospital Rooms into Smart, Connected Care Environments
Delivering Proven ROI in Smart Hospital Room Technology Across 70+ Health Systems CLEARWATER, Fla., April 15, 2025 /PRNewswire/ -- the leading AI-assisted virtual care delivery platform transforming hospital care models and operations, today announced it has raised $47 million in an oversubscribed funding growth round. The round was led by HealthQuest Capital, with participation from a strategic coalition of forward-thinking health systems and digital health investors, including Bon Secours Mercy Health, UCHealth, OSF Ventures, and LRVHealth. Already deployed across 70+ health systems, the investment fuels a period of hyper-growth for as demand accelerates for its unified virtual care platform. The platform that enables hospitals to deliver AI-assisted Virtual Nursing, Virtual Sitting, Virtual Consultation, Ambient Documentation, Digital Whiteboards, Patient Engagement, and Hospital-at-Home—all through one deeply integrated, enterprise-ready solution. The advancement and convergence of artificial intelligence and immersive virtual to physical care technologies have fueled the demand for smart hospital rooms, representing an opportunity to support healthcare delivery across the continuum of care. 'This raise represents a powerful vote of confidence in our mission and model,' said Labinot Bytyqi, Founder and CEO of 'Health systems are asking for a proven, unified virtual care platform to simplify care delivery, drive clinical efficiency, reduce burnout, and increase patient engagement—and that's exactly what we've built. With this funding, we're partnering with some of the leading health systems to scale fast and go deeper into AI to solve healthcare's toughest care delivery and operational challenges.' ' technology and vision are very closely aligned with the evolving needs of health systems,' said Randy Scott, Partner at HealthQuest Capital. 'They are solving real problems at scale, with a practical and powerful platform that delivers measurable impact.' A New Standard for Virtual Care and Patient Engagement is the only purpose-built platform on the healthcare market with a fully in-house technology stack—encompassing hardware, software, AI, and a seamless EHR integration engine. This end-to-end approach delivers unmatched speed, customization, and continuous innovation. Paired with AI and flexible hybrid clinical care team models, empowers health systems to rapidly scale hybrid care, deliver high-quality care from anywhere, and create a truly patient-centric experience—all through a single, unified platform. Trusted by Leading Health Systems Already deployed across 70+ health systems, is replacing fragmented point solutions and delivering meaningful ROI—transforming any hospital room into a smart, connected care environment. In a major milestone, AdventHealth is rolling out across more than 50 hospitals and over 13,000 patient rooms as part of an enterprise-wide implementation to enhance patient experience, streamline clinical workflows, and drive operational efficiency. Both Bon Secours Mercy Health and UCHealth are not only investors in this round but also customers of deploying the platform to reimagine virtual care delivery and elevate patient engagement across their systems. Their dual role highlights the deep alignment between innovation roadmap and the real-world needs of modern health systems. 'Our partnership with will allow us to improve safety, reduce readmissions, optimize staff workflows and improve patient experience in our hospitals,' said Mark Townsend, MD, MHCM, chief clinical digital ventures officer, Bon Secours Mercy Health and Accrete Health Partners. 'Investing in novel digital health technologies enables our health system to be at the forefront of digital transformation, with the intent of making health care as easy as possible for patients and providers.' About is a leading provider of AI-assisted virtual care solutions. Headquartered in Clearwater, FL, the company supports more than 70 health systems across the U.S. and is rapidly expanding globally. helps health systems deliver high-quality, patient-centered care while improving clinical efficiency and staff wellbeing. Its fully integrated platform includes AI-Assisted Virtual Nursing, Virtual Sitting, Patient Engagement, Digital Whiteboard, Digital Room Signage, Ambient Documentation, Hospital-at-Home, Remote Patient Monitoring (RPM), and Digital Clinic—seamlessly embedding into existing healthcare EHRs, infrastructure, and care delivery models to power the next generation of healthcare. For more information, visit About HealthQuest Capital HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately $2 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry. For more information, visit For inquiries, contact: Mimoza Buonsanti [email protected] View original content to download multimedia: SOURCE hellocare
